

Yukihiro Toi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/470559/publications.pdf>

Version: 2024-02-01

8
papers

512
citations

1478505

6
h-index

1720034

7
g-index

8
all docs

8
docs citations

8
times ranked

865
citing authors

#	ARTICLE	IF	CITATIONS
1	Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 376.	7.1	235
2	Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. <i>Oncologist</i> , 2018, 23, 1358-1365.	3.7	196
3	Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, e536-e544.	3.7	39
4	Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 4796-4804.	2.8	13
5	Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. <i>JMA Journal</i> , 2019, 3, 58-66.	0.8	13
6	Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, e410-e419.	3.7	9
7	Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). <i>Clinical Cancer Research</i> , 2022, 28, 3207-3213.	7.0	7
8	A Case of Pseudoprogression in Lung Adenocarcinoma Treated with Nivolumab. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 60-65.	0.1	0